Literature DB >> 16990762

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

R A Mesa, A Tefferi, C-Yang Li, D P Steensma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16990762     DOI： 10.1038/sj.leu.2404398

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Initial testing of lenalidomide by the pediatric preclinical testing program.

Authors:  C Patrick Reynolds; Min H Kang; Stephen T Keir; Richard Gorlick; E Anders Kolb; Richard Lock; John M Maris; Hernan Carol; Christopher L Morton; Catherine A Billups; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

2.  Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.

Authors:  Marie Luise Hütter-Krönke; Walter Fiedler; Andrea Kündgen; Jürgen Krauter; Marie von Lilienfeld-Toal; Hartmut Döhner; Richard F Schlenk
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 9.941

3.  A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

Authors:  Mikkael A Sekeres; Holly Gundacker; Jeffrey Lancet; Anjali Advani; Stephen Petersdorf; Jane Liesveld; Deborah Mulford; Tom Norwood; Cheryl L Willman; Frederick R Appelbaum; Alan F List
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

4.  Thalidomide treatment in a myelofibrosis patient with leukemia transformation.

Authors:  Wei-Han Huang; Ming-Shing Li; Sung-Chao Chu; Tso-Fu Wang; Ruey-Ho Kao; Yi-Feng Wu
Journal:  Int J Hematol       Date:  2013-12-04       Impact factor: 2.490

5.  A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Authors:  Yiming Chen; Hagop Kantarjian; Zeev Estrov; Stefan Faderl; Farhad Ravandi; Kristy Rey; Jorge Cortes; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-05-10

Review 6.  How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Authors:  Nicola Polverelli; Mirko Farina; Mariella D'Adda; Enrico Damiani; Luigi Grazioli; Alessandro Leoni; Michele Malagola; Simona Bernardi; Domenico Russo
Journal:  Cells       Date:  2022-02-05       Impact factor: 6.600

Review 7.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.